Hinge Health Earnings Call Signals Profitable Growth Path

Hinge Health, Inc. Class A ((HNGE)) has held its Q4 earnings call. Read on for the main highlights of the call.

Hinge Health’s latest earnings call struck an upbeat tone, underscoring a business that is scaling rapidly while throwing off substantial cash. Executives highlighted strong revenue growth, expanding margins, and powerful AI-driven efficiency gains, while acknowledging slower growth guidance for 2026, muted pricing power, and delayed benefits from newer initiatives like Hinge Select and Medicare-related programs.

Explosive Revenue Growth Across 2025

Hinge Health reported Q4 revenue of $171M, a 46% year-over-year increase, capping a full-year 2025 revenue figure of $588M, up 51%. Last-twelve-month calculated billings reached $671M, rising 44% and underscoring robust demand for the company’s digital musculoskeletal solutions across its expanding customer base.

Profitability Surges with Strong Free Cash Flow

Profitability moved sharply higher, with Q4 operating margin at 28% and full-year 2025 operating margin at 20%, a dramatic turnaround from negative 7% in 2024. The company generated $62M of free cash flow in Q4 and $180M for 2025, translating to free cash flow margins of 36% and 31%, respectively, signaling a capital-light, cash-rich model.

Rule of 40 Performance Far Exceeds Benchmark

Management spotlighted its Rule of 40 score of 82 in Q4 and 81 for full-year 2025, more than double the 40 threshold typically viewed as best-in-class in software and digital health. That performance reflects the rare combination of rapid top-line growth and robust free cash flow margins, positioning Hinge Health among the most efficient growth stories in its sector.

Commercial Footprint Expands Rapidly

The company added roughly 4.8M net new contracted lives in 2025, ending the year with about 24.6M contracted lives across roughly 2,800 clients, a 25% increase in clients year over year. Active members climbed to around 783,000, up 47%, highlighting growing employer and payer adoption as well as rising patient utilization of the platform.

Improving Yield and Deepening Member Engagement

Enrollment and engagement yield improved more than 50 basis points, rising from 3.4% at the end of 2024 to 3.9% at the end of 2025. Lifetime member activity topped 100M sessions, with 41M sessions in 2025 alone, equating to roughly 52 sessions per active member on an annualized basis and reinforcing the stickiness of the service.

AI Unlocks Significant Operational Leverage

The company served 47% more members in 2025 while keeping care team costs flat, reflecting substantial leverage from AI tools. Average asynchronous care team time declined 28% from March 2025 in a single quarter, and the AI care assistant, Robin, earned a 92% positive rating from early users, supporting both scalability and member satisfaction.

High Retention and Clinical Outcomes Underpin Moat

Client loyalty remained strong with 97% annual client retention in 2025 and net dollar retention well above 110%, evidencing expansion within existing accounts. Clinically, Hinge Health published its 21st peer-reviewed outcomes study, showing a 60% reduction in imaging visits at three months for chronic back program participants compared with controls, bolstering payer and employer confidence.

Guidance, Capital Strength, and Buyback Authorization

Management guided Q1 2026 revenue to $171M–$173M, implying about 39% growth at the midpoint, and expects a non-GAAP operating margin near 18%, noting Q1 is seasonally the lowest margin due to client launches. For 2026, revenue guidance of $732M–$742M and a projected 21% non-GAAP operating margin, alongside $479M in cash and a board-approved repurchase authorization, signal both financial strength and confidence in future cash generation.

Anticipated Growth Deceleration in 2026

Despite the strong 2025, management is assuming a slower trajectory, guiding to roughly 25% year-over-year revenue growth at the midpoint for 2026, down from 51% in 2025. The more measured outlook reflects deliberate conservatism, tougher comparisons, and a focus on sustainable scaling rather than chasing maximum near-term growth at the expense of profitability.

Hinge Select: Strategic, but Revenue Delayed

Hinge Select, the company’s high-performance provider network, is showing encouraging early outcomes and is viewed as a key long-term growth lever. However, management was clear that meaningful revenue impact is unlikely before at least 2027, meaning investors should not expect this initiative to materially influence near-term financials.

Engagement Yield Still Well Below Long-Term Target

While yield improved to 3.9% by the end of 2025, it remains far below the cited long-term benchmark of about 9% of U.S. adults who see a physical therapist annually. This gap highlights substantial upside potential but also underscores that future growth is heavily dependent on further gains in engagement and conversion within the existing contracted population.

Complexities Around Share Repurchases and Cash Use

The call flagged some ambiguity around capital deployment, with details on share repurchase activity juxtaposed against a board authorization of up to $250M. The reported buybacks reduced cash balances and raised investor questions about the scale and timing of repurchases relative to the stated authorization, adding a layer of complexity to Hinge Health’s capital return story.

Flat Pricing Limits Near-Term Upside

Average selling price remained essentially flat in 2025, and management’s 2026 guidance assumes ASPs stay largely unchanged, even as engagement improves. This stance suggests revenue growth will rely mainly on higher member penetration and new client wins rather than pricing power, potentially capping upside in the short term but supporting customer adoption.

Medicare and Access Program Opportunities Deferred

Management pointed to potential upside from the CMS Access program and traditional Medicare as an important strategic opportunity. However, they do not expect meaningful financial contribution in 2026, and see any material impact pushing into 2027 or later given unresolved details and pricing, keeping this catalyst firmly in the longer-term bucket.

Forward Guidance Signals Profitable, Disciplined Growth

For Q1 2026, Hinge Health expects $171M–$173M in revenue and $30M–$32M in non-GAAP operating income, reflecting an 18% margin despite launch-related costs. For the full year, guidance of $732M–$742M in revenue and $151M–$156M in non-GAAP operating income implies roughly 25% growth, a 21% margin, and a path to GAAP profitability in 2026, all built on flat yield and ASP assumptions and a modest gross margin improvement.

Hinge Health’s earnings call painted a picture of a durable growth story combining rapid expansion, rising profitability, and strong clinical validation, tempered by cautious 2026 growth assumptions and delayed contributions from newer programs. For investors, the key watch points will be continued engagement gains, the pace of AI-driven leverage, clarity on capital returns, and the eventual monetization of Hinge Select and Medicare-related opportunities.